OBJECTIVE: To assess the impact of antenatal @entity228 therapy on mortality and severe morbidities in preterm, small-for-gestational-age (SGA) neonates compared with preterm non-SGA neonates. DESIGN: Population-based study. SETTING/POPULATION: Israel National @entity600 Weight @entity1 database from 1995-2012. METHODS: Singleton @entity1 of 24-31 weeks' gestation, without major @entity600 . Antenatal @entity288 were considered either any treatment or no treatment. MAIN OUTCOME MEASURES: Univariate and multivariable logistic regression analyses were performed to assess the effect of antenatal @entity288 on neonatal mortality and a composite adverse outcome of mortality or severe neonatal morbidity. RESULTS: Among the 10 887 study @entity1 , 1771 were SGA. Of these, 70.4% of SGA and 66.7% of non-SGA neonates were exposed to antenatal @entity288 . Among SGA neonates, antenatal @entity288 were associated with decreased mortality (32.2 versus 19.3%, P < 0.0001) and composite adverse outcome (54.1 versus 43.4%, P < 0.0001), similar to the effect in non-SGA neonates (mortality 26.7 versus 12.2%, P < 0.0001; composite outcome 50.5 versus 34.6%, P < 0.0001). Multivariable logistic regression analyses demonstrated a 50% reduction in mortality risk among SGA and 57% reduction in non-SGA neonates exposed to @entity288 [OR = 0.50, 95% confidence interval (95% CI) 0.39-0.64 and OR = 0.43, 95% CI 0.38-0.47, respectively], P-value for interaction = 0.08. Composite adverse outcome risk was significantly reduced in SGA (OR = 0.67, 95% CI 0.54-0.83) and non-SGA @entity1 (OR = 0.57, 95% CI 0.52-0.63), P-value for interaction = 0.04. CONCLUSIONS: Antenatal @entity288 significantly reduced mortality and severe morbidities among preterm SGA neonates, with slightly a less pronounced effect compared with non-SGA preterm @entity1 . Antenatal @entity288 should be given to fetuses suspected of @entity1592 , at risk for @entity3152 , in order to improve perinatal outcome. TWEETABLE ABSTRACT: Antenatal @entity230 reduced mortality and severe morbidities among singleton, preterm SGA neonates.

Antenatal corticosteroid treatment in singleton, small-for-gestational-age XXXX born at 24-31 weeks' gestation: a population-based study.

@entity1 :: ('9606', 'Species') :: ['infants', 'infant'] @entity3152 :: ('MESH:D007752', 'Disease') :: ['preterm delivery'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity600 :: ('MESH:D000014', 'Disease') :: ['malformations', 'Very Low Birth'] @entity1592 :: ('MESH:D005317', 'Disease') :: ['intrauterine growth retardation'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity1 :: (9606,Species) :: ['infants']
